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The article 'Afatinib in advanced NSCLC: a profile of its use', written by Emma D. Deeks and Gillian M. Keating, was originally published Online First without open access. After Online First publication, Boehringer Ingelheim Pharmaceuticals, Inc. requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Boehringer Ingelheim Pharmaceuticals, Inc. Further details may be found <http://www.medengine.com/Redeem/C10DF0600A95D8F5>. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article was corrected.
